Mark T. Boyd

1.4k total citations
36 papers, 1.2k citations indexed

About

Mark T. Boyd is a scholar working on Molecular Biology, Oncology and Otorhinolaryngology. According to data from OpenAlex, Mark T. Boyd has authored 36 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 24 papers in Oncology and 9 papers in Otorhinolaryngology. Recurrent topics in Mark T. Boyd's work include Cancer-related Molecular Pathways (22 papers), Head and Neck Cancer Studies (9 papers) and Epigenetics and DNA Methylation (8 papers). Mark T. Boyd is often cited by papers focused on Cancer-related Molecular Pathways (22 papers), Head and Neck Cancer Studies (9 papers) and Epigenetics and DNA Methylation (8 papers). Mark T. Boyd collaborates with scholars based in United Kingdom, United States and Nigeria. Mark T. Boyd's co-authors include Nikolina Vlatković, Carlos P. Rubbi, John P. Neoptolemos, Fiona Campbell, Mark Brady, Lucie Jones, Michelle J. Humphreys, Terence M. Jones, Dale S. Haines and Radosław Polański and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Mark T. Boyd

36 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark T. Boyd United Kingdom 21 710 562 281 162 158 36 1.2k
Esra Gündüz Japan 21 858 1.2× 397 0.7× 240 0.9× 161 1.0× 88 0.6× 70 1.3k
Norishige Yamada Japan 21 754 1.1× 363 0.6× 209 0.7× 96 0.6× 281 1.8× 30 1.1k
Hiu Wing Cheung China 16 876 1.2× 457 0.8× 256 0.9× 123 0.8× 87 0.6× 36 1.3k
Yoshinori Nimura Japan 19 824 1.2× 713 1.3× 219 0.8× 133 0.8× 176 1.1× 36 1.3k
Carter Van Waes United States 18 821 1.2× 647 1.2× 408 1.5× 147 0.9× 66 0.4× 28 1.5k
John I. Song United States 16 494 0.7× 490 0.9× 256 0.9× 206 1.3× 166 1.1× 34 1.1k
Qing‐Mei He China 21 893 1.3× 287 0.5× 648 2.3× 139 0.9× 70 0.4× 44 1.3k
Ethel R. Pereira United States 13 398 0.6× 526 0.9× 236 0.8× 150 0.9× 149 0.9× 17 1.1k
Jianming Hu China 22 958 1.3× 334 0.6× 544 1.9× 235 1.5× 237 1.5× 67 1.5k
Sandra Ortiz‐Cuaran France 16 486 0.7× 527 0.9× 297 1.1× 208 1.3× 47 0.3× 35 1.0k

Countries citing papers authored by Mark T. Boyd

Since Specialization
Citations

This map shows the geographic impact of Mark T. Boyd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark T. Boyd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark T. Boyd more than expected).

Fields of papers citing papers by Mark T. Boyd

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark T. Boyd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark T. Boyd. The network helps show where Mark T. Boyd may publish in the future.

Co-authorship network of co-authors of Mark T. Boyd

This figure shows the co-authorship network connecting the top 25 collaborators of Mark T. Boyd. A scholar is included among the top collaborators of Mark T. Boyd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark T. Boyd. Mark T. Boyd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chapman, Elinor, David M. Hughes, J. Baker, et al.. (2025). Urinary metabolite model to predict the dying process in lung cancer patients. Communications Medicine. 5(1). 49–49. 1 indexed citations
2.
Chapman, Elinor, J. Baker, David M. Hughes, et al.. (2023). GC-MS Techniques Investigating Potential Biomarkers of Dying in the Last Weeks with Lung Cancer. International Journal of Molecular Sciences. 24(2). 1591–1591. 21 indexed citations
3.
Green, Daniel J., Kim Clarke, Triantafillos Liloglou, et al.. (2023). Whole genome DNA methylation and mutational profiles identify novel changes in proliferative verrucous leukoplakia. Oral Surgery Oral Medicine Oral Pathology and Oral Radiology. 135(6). 893–903. 8 indexed citations
4.
5.
Risk, Janet M., et al.. (2018). Molecular pathogenesis of proliferative verrucous leukoplakia: a systematic review. British Journal of Oral and Maxillofacial Surgery. 56(9). 780–785. 20 indexed citations
6.
Wilkie, Mark D., Andrew Lau, Nikolina Vlatković, Terence M. Jones, & Mark T. Boyd. (2015). Tumour metabolism in squamous cell carcinoma of the head and neck: an in-vitro study of the consequences of TP53 mutation and therapeutic implications. The Lancet. 385. S101–S101. 12 indexed citations
7.
Thornton, Michael, E Tweedle, Fiona Campbell, et al.. (2013). The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer. International Journal of Cancer. 133(6). 1408–1418. 48 indexed citations
8.
Vlatković, Nikolina, Mark T. Boyd, & Carlos P. Rubbi. (2013). Nucleolar control of p53: a cellular Achilles’ heel and a target for cancer therapy. Cellular and Molecular Life Sciences. 71(5). 771–791. 45 indexed citations
9.
Vlatković, Nikolina, et al.. (2011). Tissue-Specific Therapeutic Targeting of p53 in Cancer: One Size Does Not Fit All. Current Pharmaceutical Design. 17(6). 618–630. 6 indexed citations
10.
Noon, Aidan P., Radosław Polański, Helen Kalirai, et al.. (2011). Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy. British Journal of Urology. 109(8). 1250–1257. 28 indexed citations
11.
Polański, Radosław, et al.. (2011). MDM2 interacts with NME2 (non-metastatic cells 2, protein) and suppresses the ability of NME2 to negatively regulate cell motility. Carcinogenesis. 32(8). 1133–1142. 23 indexed citations
12.
Tandon, Sankalap, Catrin Tudur Smith, Richard D Riley, Mark T. Boyd, & Terence M. Jones. (2010). A Systematic Review of p53 as a Prognostic Factor of Survival in Squamous Cell Carcinoma of the Four Main Anatomical Subsites of the Head and Neck. Cancer Epidemiology Biomarkers & Prevention. 19(2). 574–587. 75 indexed citations
13.
Arya, Aditya, Asem Elfert, Richard Eccles, et al.. (2010). Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53. British Journal of Cancer. 103(2). 186–195. 54 indexed citations
14.
Jenkins, Rosalind E., et al.. (2008). MDM2 Regulates Dihydrofolate Reductase Activity through Monoubiquitination. Cancer Research. 68(9). 3232–3242. 45 indexed citations
15.
Boyd, Mark T. & Nikolina Vlatković. (2008). p53: a molecular marker for the detection of cancer. Expert Opinion on Medical Diagnostics. 2(9). 1013–1024. 19 indexed citations
16.
Brady, Mark, Nikolina Vlatković, & Mark T. Boyd. (2005). Regulation of p53 and MDM2 Activity by MTBP. Molecular and Cellular Biology. 25(2). 545–553. 59 indexed citations
17.
Brady, Mark, Madhav Bhatia, Stephen E. Christmas, et al.. (2002). Expression of the Chemokines MCP-1/JE and Cytokine-Induced Neutrophil Chemoattractant in Early Acute Pancreatitis. Pancreas. 25(3). 260–269. 55 indexed citations
18.
Boyd, Mark T., Nikolina Vlatković, & Dale S. Haines. (2000). A Novel Cellular Protein (MTBP) Binds to MDM2 and Induces a G1 Arrest That Is Suppressed by MDM2. Journal of Biological Chemistry. 275(41). 31883–31890. 84 indexed citations
19.
Boyd, Mark T., D.B. Zimonjic, N.C. Popescu, R. S. Athwal, & Dale S. Haines. (2000). Assignment<footref rid="foot01"><sup>1</sup></footref> of the MDM2 binding protein gene (MTBP) to human chromosome band 8q24 by in situ hybridization. Cytogenetic and Genome Research. 90(1-2). 64–65. 6 indexed citations
20.
Boyd, Mark T., N. Maclean, & D. Oscier. (1989). DETECTION OF RETROVIRUS IN PATIENTS WITH MYELOPROLIFERATIVE DISEASE. The Lancet. 333(8642). 814–817. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Esra Gündüz Breakdown of academic impact, for papers by Norishige Yamada Breakdown of academic impact, for papers by Hiu Wing Cheung Breakdown of academic impact, for papers by Yoshinori Nimura Breakdown of academic impact, for papers by Carter Van Waes Breakdown of academic impact, for papers by John I. Song Breakdown of academic impact, for papers by Qing‐Mei He Breakdown of academic impact, for papers by Ethel R. Pereira Breakdown of academic impact, for papers by Jianming Hu Breakdown of academic impact, for papers by Sandra Ortiz‐Cuaran
Rankless by CCL
2026